From Big Data to Precision Medicine

With the recent advances in the high-throughput sequencing technology, there is a rapid increase in volume, variety and velocity of the omics data in the field of cancer research. Now the term of “Big data” does not only mean the large data volume, but also refers to our increasing methods to analyze and interpret those data to identify the useful information with translational values for clinical application.

The goal of our lab is to fully utilize the wealth of cancer omics data from single cells to bulk tumors and develop the computational tools and methods that enable integrated analyses of the multi-omics data including whole-exome sequencing, whole-genome sequencing, transcriptome, ATAC-seq, whole genome bisulfite sequencing, ChIP-seq and Hi-C data. We aim to identify the biomarkers for cancer patient stratification and discover the new therapeutic targets for cancer treatment, especially for immunotherapy. Currently, our research focus is mainly in two types of cancer, nasopharyngeal carcinoma and esophageal squamous cell carcinoma, which have high incidence in Asian populations.

Affiliations

Our lab is in the Department of Clinical Oncology at the University of Hong Kong. We are also affiliated with the University of Hong Kong, Shenzhen Hospital.

Current Openings

For details about the positions, please visit Open positions. Please contact Dr. Wei Dai (weidai2@hku.hk) for more information about the open positions.